We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cybin (CYBN) Up on FDA Clearance of IND for CYB003 in MDD
Read MoreHide Full Article
Cybin Inc. (CYBN - Free Report) announced that it has received a received a “may proceed letter” and a clearance of the investigational new drug (“IND”) application from the FDA to begin a phase I/IIa study evaluating its pipeline candidate, CYB003.
The IND application has been cleared to evaluate Cybin’s proprietary deuterated psilocybin analog, CYB003, for the potential treatment of major depressive disorder (“MDD”). The company plans to begin recruiting patients immediately for the I/IIa study. Safety and pharmacokinetic data from the same are expected in the fourth quarter of 2022.
Shares of Cybin were up 4.7% on Monday following the announcement of the news. The stock has plunged 48.7% so far this year compared with the industry’s decline of 21.6%.
Image Source: Zacks Investment Research
Per the company, the phase I/IIa study on CYB003 will be the first time that a novel psilocybin analog is investigated for the treatment of MDD.
Earlier this month, Cybin received approval from the United States Institutional Review Board for its first-in-human phase I/IIa study evaluating CYB003 for treating MDD.
The double-blind, placebo-controlled study will investigate people with moderate to severe MDD.
In May 2022, Cybin submitted the IND for the phase I/IIa study evaluating CYB003 for treating MDD.
This apart, Cybin is looking to accelerate the clinical development of another candidate, CYB004, for the potential treatment of anxiety disorders through the planned acquisition of a phase I study from Entheon Biomedical Corp.
Cybin has no approved product in its portfolio at the moment. Therefore, successful development of its pipeline candidates remains a key focus for the company.
The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 11.1% for 2022 and 5.9% for 2023 in the past 60 days.
Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.
Aeglea BioTherapeutics’ loss per share estimates narrowed 19.4% for 2022 and 37.5% for 2023 in the past 60 days.
Earnings of Aeglea BioTherapeutics have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. AGLE delivered an earnings surprise of 9.47%, on average.
Precision BioSciences’ loss per share estimates narrowed 26.2% for 2022 and 42.6% for 2023 in the past 60 days.
Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Cybin (CYBN) Up on FDA Clearance of IND for CYB003 in MDD
Cybin Inc. (CYBN - Free Report) announced that it has received a received a “may proceed letter” and a clearance of the investigational new drug (“IND”) application from the FDA to begin a phase I/IIa study evaluating its pipeline candidate, CYB003.
The IND application has been cleared to evaluate Cybin’s proprietary deuterated psilocybin analog, CYB003, for the potential treatment of major depressive disorder (“MDD”). The company plans to begin recruiting patients immediately for the I/IIa study. Safety and pharmacokinetic data from the same are expected in the fourth quarter of 2022.
Shares of Cybin were up 4.7% on Monday following the announcement of the news. The stock has plunged 48.7% so far this year compared with the industry’s decline of 21.6%.
Image Source: Zacks Investment Research
Per the company, the phase I/IIa study on CYB003 will be the first time that a novel psilocybin analog is investigated for the treatment of MDD.
Earlier this month, Cybin received approval from the United States Institutional Review Board for its first-in-human phase I/IIa study evaluating CYB003 for treating MDD.
The double-blind, placebo-controlled study will investigate people with moderate to severe MDD.
In May 2022, Cybin submitted the IND for the phase I/IIa study evaluating CYB003 for treating MDD.
This apart, Cybin is looking to accelerate the clinical development of another candidate, CYB004, for the potential treatment of anxiety disorders through the planned acquisition of a phase I study from Entheon Biomedical Corp.
Cybin has no approved product in its portfolio at the moment. Therefore, successful development of its pipeline candidates remains a key focus for the company.
Zacks Rank & Stocks to Consider
Cybin currently carries a Zacks Rank #2 (Buy). Other stocks worth considering in the biotech sector are Leap Therapeutics, Inc. (LPTX - Free Report) , Aeglea BioTherapeutics, Inc. and Precision BioSciences, Inc. (DTIL - Free Report) , all carrying the same Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 11.1% for 2022 and 5.9% for 2023 in the past 60 days.
Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.
Aeglea BioTherapeutics’ loss per share estimates narrowed 19.4% for 2022 and 37.5% for 2023 in the past 60 days.
Earnings of Aeglea BioTherapeutics have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. AGLE delivered an earnings surprise of 9.47%, on average.
Precision BioSciences’ loss per share estimates narrowed 26.2% for 2022 and 42.6% for 2023 in the past 60 days.
Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.